[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489090":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":29,"responsibleParty":127,"collaborators":22,"id":129,"slug":22,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":22,"eligibilityCriteria":134,"healthyVolunteers":130,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":22,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":32,"whyStopped":22,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Vanda Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Iloperidone","EXPERIMENTAL","Open-label iloperidone",[13],"Drug: Iloperidone",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","oral tablet",[9],[20,21],"VYV-683","FANAPT",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Vanda Pharmaceuticals Inc.","CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[30,45,56,67,74,84,95,105,116],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Vanda Investigational Site","RECRUITING","Little Rock","Arkansas","72204","United States",{"type":38,"coordinates":39},"Point",[40,41],-92.28959,34.74648,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":46,"state":47,"zip":48,"country":36,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Denver","Colorado","80202",{"type":38,"coordinates":50},[51,52],-104.9847,39.73915,{"lat":52,"lon":51},[55],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":57,"state":58,"zip":59,"country":36,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Atlanta","Georgia","30318",{"type":38,"coordinates":61},[62,63],-84.38798,33.749,{"lat":63,"lon":62},[66],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":57,"state":58,"zip":68,"country":36,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"30331",{"type":38,"coordinates":70},[62,63],{"lat":63,"lon":62},[73],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":75,"state":58,"zip":76,"country":36,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Decatur","30030",{"type":38,"coordinates":78},[79,80],-84.29631,33.77483,{"lat":80,"lon":79},[83],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":85,"state":86,"zip":87,"country":36,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Cincinnati","Ohio","45221",{"type":38,"coordinates":89},[90,91],-84.51439,39.12711,{"lat":91,"lon":90},[94],{"name":5,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":96,"state":86,"zip":97,"country":36,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Garfield Heights","44125",{"type":38,"coordinates":99},[100,101],-81.60596,41.417,{"lat":101,"lon":100},[104],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":106,"city":107,"state":86,"zip":108,"country":36,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"NOT_YET_RECRUITING","Westlake","44145",{"type":38,"coordinates":110},[111,112],-81.91792,41.45532,{"lat":112,"lon":111},[115],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"facility":31,"status":32,"city":117,"state":118,"zip":119,"country":36,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Everett","Washington","98201",{"type":38,"coordinates":121},[122,123],-122.20208,47.97898,{"lat":123,"lon":122},[126],{"name":22,"role":26,"phone":27,"phoneExt":22,"email":22},{"type":128,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100489090",false,"NCT05648591","Safety and Tolerability of Open-Labeled Iloperidone in Adolescents","Open-label Safety Study of a 1-year 8 to 24 mg\u002FDay Dose Regimen of Iloperidone (FANAPT®) in Adolescent Patients With Schizophrenia or Bipolar I Disorder","Inclusion Criteria:\n\n* Patient is willing and able to provide assent and willing to complete all aspects of the study\n* Patient's parent or legal guardian willing and able to provide consent\n* Male or female patients 12 through 17 years of age (inclusive)\n* Clinical diagnosis of either schizophrenia or bipolar I disorder\n\nExclusion Criteria:\n\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer\n* A positive test for drugs of abuse","ALL","12 Years","17 Years",{"count":139,"type":140},100,"ESTIMATED","INTERVENTIONAL",[143],"PHASE4","To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.",[146,147],"Schizophrenia","Bipolar I Disorder",[149],"fanapt","2025-02-27",{"date":152,"type":153},"2025-03-04","ACTUAL",{"date":155,"type":153},"2023-05-24",{"date":157,"type":140},"2026-11-30",{"name":5,"class":6},9]